bioLytical Laboratories

bioLytical Laboratories

August 27, 2007 09:30 ET

bioLytical Announces Provision of INSTI™, 60-Second Rapid HIV Test, to Ontario Government

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 27, 2007) - bioLytical Laboratories (bioLytical) announced today that it has signed an agreement with Ontario to supply rapid HIV tests for the province's anonymous and sexual health clinics. INSTI™ is the only Health Canada approved rapid HIV test for point-of-care testing. The INSTI™ kit will be available free of charge to all Ontario residents through the AIDS Bureau within the Ministry of Health and Long Term Care.

This agreement follows Ontario Health Minister George Smitherman's announcement in June that Ontario would be launching the first HIV testing program in Canada. Fifty Anonymous Testing sites, along with additional point of care localities, will offer the INSTI™ kit throughout the province beginning this fall, including 24 new sites located in northern and rural Ontario. In addition to supplying INSTI™ kits to all Ontario anonymous and sexual health clinics, bioLytical will collaborate with the Minister in the development of education and promotional material to increase public awareness on HIV testing.

"We applaud the progressive HIV awareness and testing program the Ontario government has put in place," comments Carl Roy, CEO, bioLytical. "Making the INSTI™ kit available free of charge through the AIDS Bureau makes Ontario the first jurisdiction in North America to get serious about increasing HIV testing and AIDS prevention." bioLytical and the Ministry of Health through the AIDS Bureau are collaborating on a multiple site training program beginning in September.

Ontario is the largest province in the country with a population just over 12 million. Between 1985-2005, Ontario had the highest number of positive HIV test reports in Canada with a total of 26,706. Approximately 4,000 Canadians are infected with HIV each year. Research indicates that 15,000 Canadians are currently living with HIV and are unaware they are infected.

This is the first of many provincial partnerships bioLytical intends to secure in order to solidify their foothold in the rapid HIV test market. Every province in Canada has expressed their commitment to HIV/AIDS prevention and treatment. Roy is confident there will be universal availability of the INSTI™ test to ensure that people at risk of contracting or spreading the virus are identified and treated in an equitable manner wherever they live. bioLytical has also recently initiated FDA clinical trials for US approval of the test.


The INSTI™ HIV-1 Rapid Antibody Test is a rapid, in-vitro, qualitative test for the detection of antibodies to Human Immunodeficiency Virus Type 1 in human whole blood, serum or plasma. The test is capable of providing results in 60-seconds and is intended for use as a screening assay by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices.


bioLytical Laboratories (Inc.) is a leading developer and manufacturer of diagnostic tests for global health care markets. bioLytical is a privately owned company with headquarters and a state-of-the-art manufacturing facility located in Richmond, British Columbia, with offices in United Kingdom and Uganda, Africa. For more information about bioLytical and INSTI™, please visit

This news release is not, and under no circumstances is to be construed as, an
advertisement, solicitation or offering of securities of bioLytical Laboratories. The statements made in this news release may contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations.

Contact Information